Remedy's Q3 figures were softer than expected due to timing factors, but generally there was nothing surprising in the report. Remedy is now building the next growth leap of its strategy with the 5 major gaming projects under development. This will be reflected in rising costs between 2022 and 2023, but enable significant earnings growth particularly in 2025-2026, driven by increasing royalty income. Considering this long-term potential, we believe the current valuation of the stock is attractive.
Show your love by gifting this content to a fellow investor. As a Premium subscriber you can gift Premium-content to a free-user friend. Gift link: